French pharmaceutical company Servier\u2019s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, has been granted approval for use in the Boao Lecheng medical tourism pilot zone as a clinically urgently needed import drug. This approval comes in response to the pressing clinical needs for treatments targeting diffuse gliomas with IDH mutations.<\/p>\n\n\n\n
Upcoming Real-World Study in West China Lecheng Hospital<\/strong> Vorasidenib: The First Dual Inhibitor of Mutant IDH1 and IDH2<\/strong> Vorasidenib’s Status in China<\/strong> French pharmaceutical company Servier\u2019s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor,…<\/p>\n","protected":false},"author":1,"featured_media":14867,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[91],"class_list":["post-14866","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-boao-lecheng-pilot-zone"],"yoast_head":"\n
An imminent real-world study of vorasidenib is set to commence at West China Lecheng Hospital, Sichuan University. The study will focus on the drug’s efficacy and safety in patients with diffuse gliomas harboring IDH mutations, providing valuable insights into its clinical application in this specific patient population.<\/p>\n\n\n\n
Vorasidenib, the world\u2019s first dual inhibitor of mutant IDH1 and IDH2, received clearance in the US in August this year and has since been approved in Canada, Australia, Israel, Switzerland, and the United Arab Emirates. The drug is indicated for the treatment of adult and pediatric patients aged 12 years and older with grade 2 astrocytoma or oligodendroglioma, featuring a susceptible IDH1 or IDH2 mutation, who have undergone biopsy, subtotal resection, or gross total resection.<\/p>\n\n\n\n
In China, no targeted drugs for IDH mutant diffuse glioblastoma have been approved to date. However, vorasidenib has been granted approval to proceed to Phase III trials, marking a significant step towards making this treatment available to patients in need.<\/p>\n","protected":false},"excerpt":{"rendered":"